KRAS and non-small cell lung carcinoma: No approved direct targeted therapy is available for KRAS-mutant NSCLC, but two promising inhibitors—MRTX849 and AMG 510—are currently under clinical consideration with early results reporting antitumor activity in the initial patients [26,27].